Genomic classifier (ColoPrint) predicts outcome and chemotherapy benefit in stage II and III colon cancer patients

被引：0
|
作者：
Kopetz, S. [1 ]
Jiang, Z. Q. [2 ]
Overman, M. J. [1 ]
Rosenberg, R. [3 ]
Salazar, R. [4 ]
Tabernero, J. [5 ]
Stork-Sloots, L. [6 ]
Simon, I. [7 ]
Chang, G. J. [8 ]
Maru, D. M. [9 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[3] Kantonsspital Baden, Dept Surg, Baden, Switzerland
[4] Inst Catala Oncol IDIBELL Hospitalet de Llobregat, Dept Med Oncol, Barcelona, Spain
[5] Vail dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[6] Agendia, Med Affairs, Amsterdam, Netherlands
[7] Agendia, Res & Dev, Amsterdam, Netherlands
[8] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2257
引用
收藏
页码：S514 / S515
页数：2
相关论文
共 50 条
  • [21] Preoperative Neutrophil-to-Lymphocyte Ratio Predicts Clinical Outcome in Patients with Stage II and III Colon Cancer
    Absenger, Gudrun
    Szkandera, Joanna
    Stotz, Michael
    Postlmayr, Ulrich
    Pichler, Martin
    Ress, Anna Lena
    Schaberl-Moser, Renate
    Loibner, Hans
    Samonigg, Hellmut
    Gerger, Armin
    ANTICANCER RESEARCH, 2013, 33 (10) : 4591 - 4594
  • [22] THE BENEFIT OF ADJUVANT CHEMOTHERAPY FOR PATIENTS AGED 75 OR OLDER WITH STAGE III COLON CANCER
    Chen, C. H.
    Yi-Jung, W.
    Lin, T. Y.
    VALUE IN HEALTH, 2019, 22 : S442 - S442
  • [23] PERSONALIZED TREATMENT PLANNING OF STAGE II AND IIIA COLON CANCER PATIENTS USING GENOMIC CLASSIFIERS (COLOPRINT/MSI-PRINT)
    Salazar, Ramon
    Rosenberg, Robert
    Capdevila, Jaume
    Moreno, Victor
    Nitsche, Ulrich
    Bachleitner-Hofmann, Thomas
    Roepman, Paul
    Gafa, Roberta
    Lanza, Giovanni
    Tian, Sun
    Simon, Iris
    ANNALS OF ONCOLOGY, 2012, 23 : 16 - 17
  • [24] OVERUSE AND LIMITED BENEFIT OF CHEMOTHERAPY FOR STAGE II COLON CANCER IN YOUNG PATIENTS.
    Birkett, R.
    Concors, S. J.
    Saur, N. M.
    Aarons, C. B.
    Bleier, J.
    Shanmugan, S. S.
    Paulson, E.
    DISEASES OF THE COLON & RECTUM, 2018, 61 (05) : E143 - E144
  • [25] Reply: Comment on ‘A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients’
    J Szkandera
    M Pichler
    M Stotz
    A Gerger
    British Journal of Cancer, 2013, 109 : 3126 - 3127
  • [26] Reply: Comment on 'A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients'
    Szkandera, J.
    Pichler, M.
    Stotz, M.
    Gerger, A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 3126 - 3127
  • [27] Adjuvant chemotherapy for stage III colon cancer patients
    Balakrishnan, L
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (11) : 1496 - 1496
  • [28] Effect of Age on Survival Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
    Zuckerman, Ilene H.
    Rapp, Thomas
    Onukwugha, Ebere
    Davidoff, Amy
    Choti, Michael A.
    Gardner, James
    Seal, Brian
    Mullins, C. Daniel
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2009, 57 (08) : 1403 - 1410
  • [29] Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients
    van den Broek, Evert
    Krijgsman, Oscar
    Sie, Daoud
    Tijssen, Marianne
    Mongera, Sandra
    van de Wiel, Mark A.
    Belt, Eric J. Th.
    den Uil, Sjoerd H.
    Bril, Herman
    Stockmann, Hein B. A. C.
    Ylstra, Bauke
    Carvalho, Beatriz
    Meijer, Gerrit A.
    Fijneman, Remond J. A.
    ONCOTARGET, 2016, 7 (45) : 73876 - 73887
  • [30] Association of collagen deep learning classifier with prognosis and chemotherapy benefits in stage II-III colon cancer
    Jiang, Wei
    Wang, Huaiming
    Chen, Weisheng
    Zhao, Yandong
    Yan, Botao
    Chen, Dexin
    Dong, Xiaoyu
    Cheng, Jiaxin
    Lin, Zexi
    Zhuo, Shuangmu
    Wang, Hui
    Yan, Jun
    BIOENGINEERING & TRANSLATIONAL MEDICINE, 2023, 8 (03)
12345